title: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
authors.affiliation: Pharmacology Branch, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: W D
authors.initials: WD
authors.lastname: Figg
authors.forename: O
authors.initials: O
authors.lastname: Sartor
authors.forename: M R
authors.initials: MR
authors.lastname: Cooper
authors.forename: A
authors.initials: A
authors.lastname: Thibault
authors.forename: R C
authors.initials: RC
authors.lastname: Bergan
authors.forename: N
authors.initials: N
authors.lastname: Dawson
authors.forename: E
authors.initials: E
authors.lastname: Reed
authors.forename: C E
authors.initials: CE
authors.lastname: Myers
mesh_terms: D000368:Aged; D000728:Androgens / Q000819:agonists*; D005485:Flutamide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D011944:Receptors, Androgen / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000728:Androgens; D011944:Receptors, Androgen; D005485:Flutamide; D017430:Prostate-Specific Antigen